Pseudoprogression as an adverse event of glioblastoma therapy

We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...

ver descrição completa

Detalhes bibliográficos
Autores: Balana, C, Capellades, J, Pineda, E, Estival, A, Puig, J, Domenech, S, Verger, E, Pujol, T, Martinez-Garcia, M, Oleaga, L, Velarde, J, Mesia, C, Fuentes, R, Marruecos, J, Del Barco, S, Villa, S, Carrato, C, Gallego, O, Gil-Gil, M, Craven-Bartle, J, Alameda, F
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p5964
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5964
Access Level:acceso abierto
Palavra-chave:Glioblastoma
IDH1 mutation
imaging
MGMT
pseudoprogression
radionecrosis
id ES_ee39e0bc1c8f3014f522e4b48fc8ea83
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p5964
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pseudoprogression as an adverse event of glioblastoma therapyBalana, CCapellades, JPineda, EEstival, APuig, JDomenech, SVerger, EPujol, TMartinez-Garcia, MOleaga, LVelarde, JMesia, CFuentes, RMarruecos, JDel Barco, SVilla, SCarrato, CGallego, OGil-Gil, MCraven-Bartle, JAlameda, FGlioblastomaIDH1 mutationimagingMGMTpseudoprogressionradionecrosisWe explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P=0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3months; P=0.0001) but was similar for PsP and nP patients (P=0.91). OS was shorter-though not significantly sofor PsP than nP patients (OS: 19.5 vs. 27.9months; P=0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P=0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P=0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.WILEY2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5964Cancer MedicineISSN: 20457634reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p59642026-06-14T12:41:47Z
dc.title.none.fl_str_mv Pseudoprogression as an adverse event of glioblastoma therapy
title Pseudoprogression as an adverse event of glioblastoma therapy
spellingShingle Pseudoprogression as an adverse event of glioblastoma therapy
Balana, C
Glioblastoma
IDH1 mutation
imaging
MGMT
pseudoprogression
radionecrosis
title_short Pseudoprogression as an adverse event of glioblastoma therapy
title_full Pseudoprogression as an adverse event of glioblastoma therapy
title_fullStr Pseudoprogression as an adverse event of glioblastoma therapy
title_full_unstemmed Pseudoprogression as an adverse event of glioblastoma therapy
title_sort Pseudoprogression as an adverse event of glioblastoma therapy
dc.creator.none.fl_str_mv Balana, C
Capellades, J
Pineda, E
Estival, A
Puig, J
Domenech, S
Verger, E
Pujol, T
Martinez-Garcia, M
Oleaga, L
Velarde, J
Mesia, C
Fuentes, R
Marruecos, J
Del Barco, S
Villa, S
Carrato, C
Gallego, O
Gil-Gil, M
Craven-Bartle, J
Alameda, F
author Balana, C
author_facet Balana, C
Capellades, J
Pineda, E
Estival, A
Puig, J
Domenech, S
Verger, E
Pujol, T
Martinez-Garcia, M
Oleaga, L
Velarde, J
Mesia, C
Fuentes, R
Marruecos, J
Del Barco, S
Villa, S
Carrato, C
Gallego, O
Gil-Gil, M
Craven-Bartle, J
Alameda, F
author_role author
author2 Capellades, J
Pineda, E
Estival, A
Puig, J
Domenech, S
Verger, E
Pujol, T
Martinez-Garcia, M
Oleaga, L
Velarde, J
Mesia, C
Fuentes, R
Marruecos, J
Del Barco, S
Villa, S
Carrato, C
Gallego, O
Gil-Gil, M
Craven-Bartle, J
Alameda, F
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Glioblastoma
IDH1 mutation
imaging
MGMT
pseudoprogression
radionecrosis
topic Glioblastoma
IDH1 mutation
imaging
MGMT
pseudoprogression
radionecrosis
description We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P=0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3months; P=0.0001) but was similar for PsP and nP patients (P=0.91). OS was shorter-though not significantly sofor PsP than nP patients (OS: 19.5 vs. 27.9months; P=0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P=0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P=0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5964
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5964
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv Cancer Medicine
ISSN: 20457634
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423625866575872
score 15,811543

Registos relacionados